Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name	e of entity	
	Australian	n Vanadium Limited
ABN		
	90 116 221 740	
We ((the entity) give ASX the followin	g information.
_	t 1 - All issues nust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary fully paid shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,000,000

dates

+convertible

conversion)

for

payment;

securities,

conversion price and dates for

if

the

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes – The shares will rank equally in all respects with fully paid shares currently on issue.
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment	
	 the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	\$0.014712
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of unlisted options exercisable at \$0.014712 each on or before 31 December 2017
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	23 November 2016
6c	Number of *securities issued without security holder approval under rule 7.1	Nil

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

	6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
	6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
	6f	Number of *securities issued under an exception in rule 7.2	1,000,000	
	6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
	6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
	6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 – 1. Listing Rule 7.1A –	
<u>as</u>	7	⁺ Issue dates	13 July 2017	
		Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.		
			Number	+Class
	8	Number and +class of all +securities quoted on ASX	Number 1,216,734,216	Ordinary shares
		*securities quoted on ASX (including the *securities in section 2 if applicable)	235,884,557	Options (31/12/2018; \$0.02)

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
80,000,000	Partly paid shares
141,960,353	Options exercisable at \$0.014712 each on or before 31/12/2017
15,000,000	Performance Rights expiring 2 February 2020
40,000,000	Class A Performance Rights expiring 19 June 2018 (1:1 ratio)
40,000,000	Class B Performance Rights expiring 19 December 2019 (1:1 ratio)
20,000,000	Performance Rights expiring 19 December 2019 (1:1 ratio)
20,000,000	Performance Rights expiring 19 December 2020 (1:1 ratio)
20,000,000	Performance Rights expiring 19 December 2021 (1:1 ratio)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

11	Is security required?	holder	approval	-

- Is the issue renounceable or non-renounceable?
- Ratio in which the *securities will be offered -
- ⁺Class of ⁺securities to which the offer relates -
- 15 ⁺Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- Policy for deciding entitlements in relation to fractions

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents	-
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	-
20	Names of any underwriters	-
21	Amount of any underwriting fee or commission	-
22	Names of any brokers to the issue	-
23	Fee or commission payable to the broker to the issue	-
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	-
25	If the issue is contingent on security holders' approval, the date of the meeting	-
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	-
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	-
28	Date rights trading will begin (if applicable)	-
29	Date rights trading will end (if applicable)	-
30	How do security holders sell their entitlements <i>in full</i> through a broker?	-

⁺ See chapter 19 for defined terms.

Appendix 3B	
New issue an	nouncemen

31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	
	3 - Quotation of securities eed only complete this section if you are apply	ying for quotation of securities
34	Type of ⁺ securities (<i>tick one</i>)	
(a)	*Securities described in Part 1	
(b)	•	of the escrowed period, partly paid securities that become fully paid, estriction ends, securities issued on expiry or conversion of convertible
Entiti	ies that have ticked box 34(a)	
Addi	tional securities forming a new c	lass of securities
Tick to	o indicate you are providing the information nents	n or
35	1 1	curities, the names of the 20 largest holders of the number and percentage of additional *securities
36	1 1	ecurities, a distribution schedule of the additional ber of holders in the categories
37	A copy of any trust deed for th	e additional ⁺ securities

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Number of *securities for which -	
†quotation is sought	
39 *Class of *securities for which quotation is sought -	
Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest	
payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	
(if issued upon conversion of another *security, clearly identify that other *security)	
Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: N J Bassett Date: 13 July 2017

(Director/Company secretary)

Print name: Neville John Bassett

== == == ==

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 –	Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the ba	Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue		1,002,118,601		
Add the following:	Issue of shares on exercise of options (15/8/16)	12,750,000		
Number of fully paid +ordinary	Issue of shares on exercise of options (19/8/16)	47,386,773		
securities issued in that 12 month period under an	Issue of shares on conversion of performance shares	15,000,000		
exception in rule 7.2	Issue of shares on exercise of options (6/9/16)	13,860,000		
Number of fully paid ⁺ ordinary securities issued in that 12	Issue of shares on exercise of options (22/9/16)	8,178,842		
month period with shareholder	Issue of shares on exercise of options (24/10/16)	2,000,000		
approval	Issue of shares on exercise of options (16/2/17)	25,000,000		
 Number of partly paid ⁺ordinary securities that became fully paid 	Issue of shares on exercise of options (3/3/17)	4,190,000		
in that 12 month period	Issue of shares on exercise of options (30/3/17)	2,000,000		
Note: Include only ordinary securities	Issue of shares (15/11/16)	7,000,000		
here – other classes of equity	Issue of shares (20/12/16)	70,000,000		
securities cannot be added Include here (if applicable) the	Issue of shares (15/3/17)	6,250,000		
securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	Issue of shares on exercise of options (13/7/17)	1,000,000		
Subtract the number of fully paid †ordinary securities cancelled during that 12 month period		Nil		
"A"		1,216,734,216		

⁺ See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	182,510,132
Step 3: Calculate "C", the amou	nt of placement capacity under rule
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	
Step 4: Subtract "C" from ["A" x placement capacity under rule 7	-
"A" x 0.15	182,510,13
Note: number must be same as shown in Step 2	
Subtract "C"	
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	182,510,13
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	121,673,421
Step 3: Calculate "E", the amount 7.1A that has already been used Insert number of *equity securities issued	of placement capacity under rule
or agreed to be issued in that 12 month period under rule 7.1A	INII
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	Nil

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	121,673,421
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	121,673,421
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.